FDA 2.0: Will an Image Makeover Help Restore FDA's Credibility?
This article was originally published in RPM Report
Executive Summary
A new website, partnership agreements with health information disseminators and a beefed up public relations staff are all aimed at improving FDA’s consumer outreach messaging. Is it working?
You may also be interested in...
Avandia and the Commercial Impact of FDA's Credibility Gap
GlaxoSmithKline's diabetes drug Avandia survived a perilous FDA advisory committee review. The real question is whether the industry can survive the damage to FDA's credibility.
Avandia and the Commercial Impact of FDA's Credibility Gap
GlaxoSmithKline's diabetes drug Avandia survived a perilous FDA advisory committee review. The real question is whether the industry can survive the damage to FDA's credibility.
Aranesp Awaits Label Transplant As Committee Mulls Alternate Trial Designs
Amgen avoided an immediate setback when a Cardiovascular and Renal Drugs Advisory Committee meeting on Oct. 18 voted against further restrictions on the use of Aranesp (darbepoetin alfa) in chronic kidney disease (CKD) patients.